The Global ADHD Therapeutics Market was valued $xx Mn in 2019 and is expected to reach $25.95 Bn by 2026, at a CAGR of 6.27%.
Market Introduction and OverviewAttention Deficit-Hyperactivity Disorder (ADHD) is a psychiatric condition that has long been recognized as affecting children's ability to function. Individuals suffering from this disorder show patterns of developmentally inappropriate levels of inattentiveness, hyperactivity, or impulsivity. Since the past decade, the concept of ADHD seems to have become a broader and more heterogeneous. However, the diagnosis and treatment of ADHD are still challenging for clinicians, necessitating increased reliance on their expertise and experience. Increasing prevalence of ADHD and advancements in the therapeutics to manage the conditions are key driving forces behind the growth of the market. Increase in the uses of medicines to treat ADHD presage towards the growth in the number of cases diagnosed and treated. Recent decades have seen a growth in treatments for attention deficit hyperactivity disorder (ADHD) including many branded and generic drugs. In the early 2000's, new drug entry dramatically altered market shares. The introduction of new products expands the range of consumer choice and increases consumer welfare. Prescriptions for ADHD medication have steadily increased over the last decade, leading to important expenditure to public payer health care systems. Pharmacologic treatment options for ADHD in adults comprise both psycho-stimulant and non-stimulant options. Additionally, increasing advancements in the medical field, expanding focus on biotechnology and pharmaceutical companies in development of innovative therapeutics for ADHD are also driving the market demand. The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. The report contains a detailed analysis of Strengths, Weakness and opportunities of the key players operating in the ADHD Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges.
Segment AnalysisBy drug type, the stimulants segment was valued $xx Mn in 2020, and is expected to dominate the ADHD market in the forecast period. The stimulants are considered first-line treatments for ADHD, supported by decades of research and a history of robust response, good tolerability, and safety across the lifespan. Stimulants are classified by the US Food and Drug Administration (FDA) and the Drug Enforcement Agency as schedule 2 agents. Non-stimulant treatments are also available among current medical treatment options. A combination of pharmacological and psychological therapies are recommended for the treatment of ADHD and a number of different medications (stimulants and non-stimulants) which are licensed in the US and Europe have been shown to have both efficacy and tolerability. Stimulant medications are leading to a clinically significant reduction of symptoms in around 70 percent of cases. In addition, they have also shown some efficacy in the treatment of other conditions, such as narcolepsy and resistant depression. These factors are contributing in the expansion of the ADHD market. The Lisdexamfetamine Dimesylate drug type sub-segment is expected to register highest CAGR of 15.6% in the forecast period. The longer effectiveness of the treatment and easier availability is expected to grow the segment. The Lisdexamfetamine Dimesylate drug type sub-segment is expected to reach a market value of US$ 5,682.2 Mn by the end of 2024. By distribution channel, retail pharmacy accounted for the largest share of xx% in 2020, due to increasing number of prescriptions. This can be attributed to rise in patient care initiatives by retail pharmacies. Patients prefer purchasing drugs from retail pharmacies rather than hospitals and therefore, the segment is expected to retain its lead throughout the forecast period. To know about the Research Methodology :- Request Free Sample Report
Regional InsightsThe ADHD market of North America is expected to dominate the market accounting for nearly xx% of the total market share and registering a CAGR of xx% in the forecast period. Growing mergers & acquisitions is observed among in-vitro diagnostic and life sciences players in North America. This is anticipated to largely propel the region’s growth in the future. Key market players are strengthening their product portfolio by venturing into various medical specialty domains. In March 2019, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received the U.S. Food and Drug Administration (FDA) approval for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, for the treatment of attention-deficit hyperactivity disorder (ADHD). The European ADHD market holds the second-most position owing to the emerging technologies and digital medicines in the region. The expanding medical devices market and growing healthcare expenditure are augmenting the market growth. Asia-Pacific is also expected to grow fast, at a CAGR of xx% in the forecast period. This growth is attributed to the unmet needs and sizeable patient population. Developing economies in the APAC region are affecting the market positively. The availability of low cost drugs for ADHD treatment and increased funding from private organisations are key factors driving the market growth. Healthcare insurance policies in countries such as Malaysia, Vietnam and Thailand are up surging the APAC ADHD market. Moreover, the emergence, availability and acceptance of innovative technologies is propelling the market.
Scope of the Report: Inquire before Buying
Report Coverage Details
By Region• North America • Europe • South America • MEA • Asia Pacific
Key Players Operating in the Global ADHD Therapeutics Market• Eli Lily & Company • Pfizer • Johnson & Johnson Services, LLC • Lupin • Shire • Mallinckrodt • Prude Pharma L.P. • NEOS Therapeutics Inc • Amneal Pharmaceuticals, Inc • Janssen Pharmaceuticals, Inc • Noven Pharmaceuticals Inc, • RespireRx Pharmaceuticals Inc • Otsuka Pharmaceutical Co., Ltd • Neos Therapeutics, Inc. • American Brivision (Holding) Corporation • Novartis International AG • Takeda Pharmaceutical Company Limited • GlaxoSmithKline plc The report also helps in understanding Global ADHD Therapeutics Market dynamics, structure by analysing the market segments and project the Global ADHD Therapeutics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global ADHD Therapeutics Market make the report investor’s guide.
1. Global ADHD Therapeutics Market: Research Methodology 2. Global ADHD Therapeutics Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global ADHD Therapeutics Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global ADHD Therapeutics Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global ADHD Therapeutics Market Segmentation 4.1 Global ADHD Therapeutics Market, by Drug Type (2020-2026) • Stimulants • Non-stimulants 4.2 Global ADHD Therapeutics Market, by Distribution Channel (2020-2026) • Retail Pharmacy • Hospital Pharmacy 5. North America ADHD Therapeutics Market(2020-2026) 5.1 North American ADHD Therapeutics Market, by Drug Type (2020-2026) • Stimulants • Non-stimulants 5.2 North America ADHD Therapeutics Market, by Distribution Channel (2020-2026) • Retail Pharmacy • Hospital Pharmacy 5.3 North America ADHD Therapeutics Market, by Country (2020-2026) • United States • Canada • Mexico 6. Asia Pacific ADHD Therapeutics Market (2020-2026) 6.1. Asia Pacific ADHD Therapeutics Market, by Drug Type (2020-2026) 6.2. Asia Pacific ADHD Therapeutics Market, by Distribution Channel (2020-2026) 6.2. Asia Pacific ADHD Therapeutics Market, by Country (2020-2026) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa ADHD Therapeutics Market (2020-2026) 7.1. Middle East and Africa ADHD Therapeutics Market, by Drug Type (2020-2026) 7.2. Middle East and Africa ADHD Therapeutics Market, by Distribution Channel (2020-2026) 7.3. Middle East and Africa ADHD Therapeutics Market, by Country (2020-2026) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America ADHD Therapeutics Market (2020-2026) 8.1. Latin America ADHD Therapeutics Market, by Drug Type (2020-2026) 8.2. Latin America ADHD Therapeutics Market, by Distribution Channel (2020-2026) 8.3 Latin America ADHD Therapeutics Market, by Country (2020-2026) • Brazil • Argentina • Rest Of Latin America 9. European ADHD Therapeutics Market (2020-2026) 9.1. European ADHD Therapeutics Market, by Drug Type (2020-2026) 9.2. European ADHD Therapeutics Market, by Distribution Channel (2020-2026) 9.3 European ADHD Therapeutics Market, by Country (2020-2026) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. Eli Lily & Company. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Pfizer 10.3. Johnson & Johnson Services, LLC 10.4. Lupin 10.5. Shire 10.6. Mallinckrodt 10.7. Prude Pharma L.P. 10.8. NEOS Therapeutics Inc 10.9. Amneal Pharmaceuticals, Inc 10.10. Janssen Pharmaceuticals, Inc 10.11. Noven Pharmaceuticals Inc, 10.12. RespireRx Pharmaceuticals Inc 10.13. Otsuka Pharmaceutical Co., Ltd 10.14. Neos Therapeutics, Inc. 10.15. American Brivision (Holding) Corporation 10.16. Novartis International AG 10.17. Takeda Pharmaceutical Company Limited 10.18. GlaxoSmithKline plc